S
SAGE Therapeutics
Develops and delivers novel medicines for most debilitating and disabling central nervous system disorders
At a glance
- Founded
- 2010
- Headquarters
- Raleigh, United States
- Listing
- IPO 2014
- Sector
- Biotech & Life Sciences
- Power Law
- Unicorn$1–10B valuation tierThoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later5 investors entered at this stage
ARCH Venture Partners- WLWashington University in St. Louis
Foresite Capital
OrbiMed- ECEcoR1 Capital
Source: Dealroom Talent Intelligence.
Alumni founders
Former SAGE Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
PMPraxis Precision MedicinesEst. 2015
Kiran ReddyUnited States
MMModel MedicinesEst. 2019
VTVoyager TherapeuticsEst. 2014
Steven PaulUnited States
NBNido BiosciencesEst. 2018
Jamil BegUnited States
TNTortugas NeuroscienceEst. 2024
Albert J. RobichaudUnited StatesGlobal footprint
team presence
across markets
Patents
124 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about SAGE Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SAGE Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.